2-(2-羟基乙基)-3-甲基-1-氧代-1,5-二氢吡啶并[1,2-A]苯并咪唑-4-甲腈 | 166671-26-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-(2-羟基乙基)-3-甲基-1-氧代-1,5-二氢吡啶并[1,2-A]苯并咪唑-4-甲腈
• 中文别名: 2-(1-(3-氟苯基)-1H-5-吡唑基)噻唑
• 英文名称: 2-(2-hydroxyethyl)-3-methyl-1-xo-1H,5H-pyrido<1,2-a>benzimidazole-4-carbonitrile
• 英文别名: 2-(2-hydroxyethyl)-3-methyl-1-oxo-1H,5H-pyrido[1,2-a]benzimidazole-4-carbonitrile；2-(2-Hydroxyethyl)-3-methyl-1-oxo-1,5-dihydropyrido[1,2-a]benzimidazole-4-carbonitrile；2-(2-hydroxyethyl)-3-methyl-1-oxo-5H-pyrido[1,2-a]benzimidazole-4-carbonitrile
• CAS: 166671-26-7
• 化学式: C₁₅H₁₃N₃O₂
• 分子量: 267.287
• InChiKey: FNCJHHFYZDSIAK-UHFFFAOYSA-N

物化性质

• 熔点：
  250 °C
• 溶解度：
  19 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  76.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090
• 安全说明：
  S36/37

反应信息

• 作为反应物：
  描述：

  2-(2-羟基乙基)-3-甲基-1-氧代-1,5-二氢吡啶并[1,2-A]苯并咪唑-4-甲腈 在 氯化亚砜 、 sodium azide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 、 苯 为溶剂， 反应 7.75h， 生成 3-methyl-2-(2-triphenylphosphoranylideneaminoethyl)-1-oxo-1H,5H-pyrido<1,2-a>benzymidazole-4-carbonitrile
  参考文献：
  名称：

  Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-α]benzimidazoles and related derivative

  摘要：

  Some pyrido[1,2-a]benzimidazoles were prepared in order to investigate their in vitro antineoplastic and anti-HIV activities. Two compounds (9b, NSC 658526 and 15, NSC 664715) showed a variable degree of antineoplastic activity against some of the cell lines tested. Compound 9a (NSC 649900) exhibited a good in vitro antineoplastic activity with subpanel disease selectivity, particularly against most of the cell lines of leukemia and some cell lines from colon, melanoma and renal cancer panels.

  DOI：

  10.1016/0223-5234(96)88241-9
• 作为产物：
  描述：

  α-乙酰基-γ-丁内酯 、 2-氰甲基苯并咪唑 在 乙酸铵 作用下， 反应 1.0h， 以90%的产率得到2-(2-羟基乙基)-3-甲基-1-氧代-1,5-二氢吡啶并[1,2-A]苯并咪唑-4-甲腈
  参考文献：
  名称：

  Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-α]benzimidazoles and related derivative

  摘要：

  Some pyrido[1,2-a]benzimidazoles were prepared in order to investigate their in vitro antineoplastic and anti-HIV activities. Two compounds (9b, NSC 658526 and 15, NSC 664715) showed a variable degree of antineoplastic activity against some of the cell lines tested. Compound 9a (NSC 649900) exhibited a good in vitro antineoplastic activity with subpanel disease selectivity, particularly against most of the cell lines of leukemia and some cell lines from colon, melanoma and renal cancer panels.

  DOI：

  10.1016/0223-5234(96)88241-9

文献信息

• Imidazo[1,2-a]pyridine derivative
  申请人：Takemura Makoto

  公开号：US20050113397A1

  公开（公告）日：2005-05-26

  A compound reprsented by the following formula (I), its salts or nsolvates thereof capable of specifically or selectively expressig an antifungal activity in a broad spectrum based on the novel mechanism thereof of 1,6-β-glucan synthesis inhibition, and an antifungal agent containing any of them.

  以下化学式（I）所代表的化合物，其盐或无溶剂物，能够基于其新颖的机制——1,6-β-葡聚糖合成抑制，具有广谱的特异性或选择性抗真菌活性，以及含有其中任何一种的抗真菌剂。
• IMIDAZO(1,2-a)PYRIDINE DERIVATIVE
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1479681A1

  公开（公告）日：2004-11-24

  A compound reprsented by the following formula (I), its salts or nsolvates thereof capable of specifically or selectively expressig an antifungal activity in a broad spectrum based on the novel mechanism thereof of 1,6-β-glucan synthesis inhibition, and an antifungal agent containing any of them.

  下式(I)所代表的化合物、其盐类或溶液剂，根据其抑制 1，6-β-葡聚糖合成的新机理，能够特异性或选择性地表达广谱抗真菌活性，以及含有它们中任何一种的抗真菌剂。
• EP1479681
  申请人：——

  公开号：——

  公开（公告）日：——
• Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-α]benzimidazoles and related derivative
  作者：E Badawey、T Kappe

  DOI：10.1016/0223-5234(96)88241-9

  日期：1995.1

  Some pyrido[1,2-a]benzimidazoles were prepared in order to investigate their in vitro antineoplastic and anti-HIV activities. Two compounds (9b, NSC 658526 and 15, NSC 664715) showed a variable degree of antineoplastic activity against some of the cell lines tested. Compound 9a (NSC 649900) exhibited a good in vitro antineoplastic activity with subpanel disease selectivity, particularly against most of the cell lines of leukemia and some cell lines from colon, melanoma and renal cancer panels.